IBCSG 28-02 / BIG 1-01 (HERA)

  • HERA: A randomized, three-arm, multicenter comparison of 1 year and 2 years of herceptin vs. no herceptin in women with HER2 positive primary breast cancer who have completed adjuvant chemotherapy

  • Study Chairs
    IBCSG: Dr. Olivia Pagani - Mendrisio, Switzerland
    BIG: Dr. Martine J. Piccart - Brussels, Belgium

    Director of the Data Management Center
    Holly Shaw

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Date of Activation
    December 2001

    Date of Closure
    June 20, 2005

    Targeted Accrual
    2730 patients

    Final Accrual
    5102 patients

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login